Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: German Federal Patent Court releases new decision


In the present decision, the German Federal Patent Court dealt with the question of which point in time is decisive when considering advantages and technical effects of a claimed technical teaching. This question can be of importance both in the context of inventive step discussions in nullity cases and in the context of the technical-functional interpretation as applied by the infringement courts.

The German Federal Patent Court ruled that only the disclosure of the patent application would be decisive and that only those advantages and technical effects can be applied which the skilled person has been able to recognise at the filling date. According to the German Federal Patent Court, an objective enrichment of the prior art should only be considered as it is recognisable for a skilled person on the basis of the disclosure of the patent application or on the basis of his knowledge at the filling date. It is not sufficient that such an advantage or technical effect existed objectively unrecognised at the time of filing, but is only subsequently recognisable by the skilled person and made accessible as such.

In its first guideline, the German Federal Patent Court stated:

To the extent that the case-law and the literature refer to the granted patent with respect to a disclosure of advantages and effects, the relevant disclosure of the patent application must be taken into account instead – the granted patent does not represent an additional caesura for an admissible fall back on the original disclosure of the patent application within the limits of the exclusion of an extension of the scope of protection.

With its decision, the German Federal Patent Court has sparked a discussion on the relationship between the disclosure of a patent application and a disclosure of the later granted patent which may differ from the disclosure of the patent application. This discussion may also have an impact on the technical-functional interpretation as applied by the infringement courts, as they have so far mainly focused on the disclosure of the granted patent. Notably, in its decision Occlusion Device (BGHZ 189, 330 = GRUR 2011, 701 – Okklusionsvorrichtung), the German Federal Supreme Court stated that the interpretation of the claim features could possibly also be based on a difference between a published patent application and the later granted patent. It therefore remains to be seen how the infringement courts and the German Federal Supreme Court will position themselves in this regard.

Again, it must be noted that it is of crucial importance, when drafting patent applications, to sufficiently explain the advantages and technical effects to be achieved with the respective features in order to be able to argue accordingly in subsequent nullity proceedings or infringement proceedings.


Stefan Bianchin


Elisenhof, Elisenstraße 3

D-80335 München

Tel: +49 (0)89 747266-0

Fax: +49 (0)89 776424

more from across site and ros bottom lb

More from across our site

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
With business confidence in a shaky state, Rachel Tong and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel
Previous attempts at major transatlantic tie-ups have failed, so lawyers will keep their eyes firmly on Allen & Overy’s grand plans
INTA CEO Etienne Sanz de Acedo shares his plans if he were to win the EUIPO leadership race and says his application does not affect his INTA role
The French finance minister told António Campinos the timing of an EPO event in Lisbon could be seen as interference in the EUIPO leadership race